PMOS (Polycystic Metabolic Ovarian Syndrome): What Has Changed with the New 2026 Definition
In 2026, leading international scientific societies—including the European Society of Endocrinology (ESE) and the Androgen Excess and PCOS Society—adopted updated terminology to describe the syndrome: from PCOS (Polycystic Ovary Syndrome) to PMOS (Polycystic Metabolic Ovarian Syndrome). This change in nomenclature reflects a profoundly renewed understanding of the disease.
Why the Change from PCOS to PMOS
The old designation "polycystic ovary syndrome" carried three fundamental problems:
- It emphasized the ovaries as the main site of the problem, when research over the last 15 years has clarified that insulin resistance and metabolic dysfunction are the primary cause, not a consequence.
- It excluded the metabolic context: many women sought only treatments for acne and irregular periods, without the doctor addressing the risk of type 2 diabetes, cardiovascular disease, and metabolic syndrome.
- "Polycystic" was misleading: ovarian cysts on ultrasound are present in only 2/3 of PCOS cases; many women with the syndrome do not have them—and many healthy women do.
The new definition PMOS—Polycystic Metabolic Ovarian Syndrome—shifts the focus:
- It recognizes metabolic dysfunction as a central, not secondary, element.
- It explicitly includes insulin resistance as a key diagnostic criterion.
- It promotes an integrated therapeutic approach that includes glycemic control and body composition, not just cycle regularization.
The New 2026 PMOS Diagnostic Criteria
The ESE/AE-PCOS 2026 task force proposed a 3-axis system:
| Axis | Criteria | Assessment Method |
|---|---|---|
| Axis 1: Ovarian | Oligoanovulation (<8 cycles/year) and/or polycystic ovarian morphology on high-resolution ultrasound | Transvaginal ultrasound with ≥8 MHz probe |
| Axis 2: Androgenic | Clinical hyperandrogenism (acne, hirsutism, alopecia) or biochemical (elevated free testosterone, increased free androgen index) | Hormone assay (total/free testosterone, SHBG, DHEA-S) |
| Axis 3: Metabolic (new) | Insulin resistance (HOMA-IR ≥2.5 or fasting insulin ≥12 µU/mL) and/or metabolic syndrome (≥3 IDF criteria) | Fasting insulin + HOMA-IR; lipid panel; waist circumference |
PMOS is diagnosed with ≥2 positive axes. Axis 3 (metabolic) can replace Axis 1 as the second criterion—recognizing that many women with significant metabolic dysfunction have normal or near-normal cycles.
What Changes in Clinical Practice
For diagnosis
- Fasting insulin and HOMA-IR become routine tests in PMOS workup—no longer requested only in cases of "suspected insulin resistance."
- OGTT with insulin curve (not just glucose) is recommended for women with regular cycles but other present criteria.
- Body composition (BIA scale or DEXA) is included in recommendations as a tool for visceral fat assessment.
For treatment
- Metformin becomes first-line treatment not only for "obese" women with PMOS but for all those with elevated HOMA-IR, regardless of weight.
- Home glycemic monitoring is included in recommendations for women with PMOS in pre-diabetes or with borderline fasting glucose.
- Therapeutic goals now explicitly include: HOMA-IR <2.5, fasting glucose <100 mg/dL, triglycerides <150 mg/dL—not just cycle regularization.
For long-term monitoring
- Annual blood glucose and HbA1c screening—no longer every 2–3 years as in old PCOS guidelines.
- Semi-annual blood pressure check.
- Annual lipid panel.
- Liver ultrasound every 2 years (PMOS is associated with fatty liver disease in 30–40% of cases).
PMOS and Home Monitoring
The new PMOS classification emphasizes the importance of proactive home monitoring. Two tools become central:
- Glucometer: Women with PMOS can have an elevated postprandial glycemic response even with normal fasting glucose. Measuring 1h after meals allows for early identification of insulin resistance and personalized dietary optimization. The G1 Pro—with Bluetooth and app—is the ideal tool for building a continuous glycemic diary to share with your doctor.
- Body impedance scale: Visceral fat—now an explicit metabolic criterion in PMOS—is better monitored with BIA than with waist circumference alone. The Brio 1 Pro measures visceral fat (scale 1–59) and full body composition at each weighing.
Frequently Asked Questions
I already have a PCOS diagnosis—do I need to get re-diagnosed as PMOS?
There's no need to formally re-diagnose—PMOS is a terminological evolution of the same condition. What matters practically is that your doctor also evaluates the metabolic component (insulin, HOMA-IR, lipid profile) if it hasn't been done yet.
Does PMOS also affect lean women?
Yes. Metabolic dysfunction in PMOS is not synonymous with overweight: many women with normal-weight PMOS have elevated HOMA-IR and hyperinsulinemia. The new classification explicitly recognizes this aspect—which old guidelines often underestimated.
